BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22377706)

  • 1. Soluble mesothelin-related peptides levels in patients with malignant mesothelioma.
    Franko A; Dolzan V; Kovac V; Arneric N; Dodic-Fikfak M
    Dis Markers; 2012; 32(2):123-31. PubMed ID: 22377706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos.
    Filiberti R; Marroni P; Spigno F; Merlo DF; Mortara V; Caruso P; Cioè A; Michelazzi L; Bruzzone A; Bobbio B; Simonassi C; Del Corso L; Galli R; Racchi O; Dini G; Linares R; Mencoboni M
    Oncology; 2014; 86(1):33-43. PubMed ID: 24401539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
    Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
    Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
    Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
    Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
    Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
    Bonotti A; Simonini S; Pantani E; Giusti L; Donadio E; Mazzoni MR; Chella A; Marconi L; Ambrosino N; Lucchi M; Mussi A; Cristaudo A; Foddis R
    Int J Biol Markers; 2017 Mar; 32(1):e126-e131. PubMed ID: 27646775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating SMRP and CA-125 before and after pleurectomy decortication for pleural mesothelioma.
    Paajanen J; Sadek A; Richards WG; Xie Y; Mazzola E; Sidopoulos K; Kuckelman J; Gill RR; Bueno R
    Thorac Cancer; 2024 May; 15(15):1237-1245. PubMed ID: 38627917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
    Wheatley-Price P; Yang B; Patsios D; Patel D; Ma C; Xu W; Leighl N; Feld R; Cho BC; O'Sullivan B; Roberts H; Tsao MS; Tammemagi M; Anraku M; Chen Z; de Perrot M; Liu G
    J Clin Oncol; 2010 Jul; 28(20):3316-22. PubMed ID: 20498407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
    Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
    Cristaudo A; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Chella A; Lucchi M; Mussi A; Foddis R
    J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two novel polymorphisms in 5' flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels.
    Cristaudo A; Foddis R; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Bruno R; Gemignani F; Landi S
    Int J Biol Markers; 2011; 26(2):117-23. PubMed ID: 21574151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
    Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
    Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individual predictors of increased serum mesothelin in asbestos-exposed workers.
    Filiberti R; Marroni P; Mencoboni M; Mortara V; Caruso P; Cioè A; Michelazzi L; Merlo DF; Bruzzone A; Bobbio B; Del Corso L; Galli R; Taveggia P; Dini G; Spigno F
    Med Oncol; 2013 Mar; 30(1):422. PubMed ID: 23277285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MESOMARK: a potential test for malignant pleural mesothelioma.
    Beyer HL; Geschwindt RD; Glover CL; Tran L; Hellstrom I; Hellstrom KE; Miller MC; Verch T; Allard WJ; Pass HI; Sardesai NY
    Clin Chem; 2007 Apr; 53(4):666-72. PubMed ID: 17289801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels.
    Rai AJ; Flores RM; Mathew A; Gonzalez-Espinoza R; Bott M; Ladanyi M; Rusch V; Fleisher M
    Clin Chem Lab Med; 2010 Feb; 48(2):271-8. PubMed ID: 20131968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma.
    Weber DG; Taeger D; Pesch B; Kraus T; Brüning T; Johnen G
    Cancer Biomark; 2007; 3(6):287-92. PubMed ID: 18048966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
    J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma.
    Nelson HH; Almquist LM; LaRocca JL; Plaza SL; Lambert-Messerlian GM; Sugarbaker DJ; Bueno R; Godleski JJ; Marsit CJ; Christensen BC; Kelsey KT
    Epigenetics; 2011 Aug; 6(8):1029-34. PubMed ID: 21775819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
    Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.